Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCALATE: Colchicine in High-risk Chronic Coronary Syndromes
NCT06469528Phase 3Not yet recruiting
- Sponsor
- King's College Hospital
- Start
- Jun 2024
- Primary completion
- Oct 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, open-label trial of colchicine in coronary artery disease (CAD) (2 arms), sponsored by King's College Hospital. Primary endpoint: Absolute change in minimal fibrous cap thickness at 6 months. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06469528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469528.